	US 12,239,745 B2
	Formulation
Roderick Bowers, Lanarkshire (GB); Magdalena Switnicka-Plak, Lanarkshire (GB); Neil Graham, Lanarkshire (GB); James Carnegie, Lanarkshire (GB); Gordon Honeyman, Lanarkshire (GB); and Abdul Rashid, Lanarkshire (GB)
Assigned to Ocutec Limited, Lanarkshire (GB)
Appl. No. 17/268,282
Filed by OCUTEC LIMITED, Lanarkshire (GB)
PCT Filed Aug. 13, 2019, PCT No. PCT/GB2019/052280 § 371(c)(1), (2) Date Feb. 12, 2021, PCT Pub. No. WO2020/035681, PCT Pub. Date Feb. 20, 2020.
Claims priority of application No. 1813229 (GB), filed on Aug. 14, 2018.
Prior Publication US 2021/0316035 A1, Oct. 14, 2021
Int. Cl. A61L 12/12 (2006.01); A61L 15/22 (2006.01); A61L 15/42 (2006.01); A61L 29/08 (2006.01); A61L 29/14 (2006.01); G02B 1/04 (2006.01)

CPC A61L 12/12 (2013.01) [A61L 15/225 (2013.01); A61L 15/42 (2013.01); A61L 29/085 (2013.01); A61L 29/14 (2013.01); A61L 2420/06 (2013.01); G02B 1/043 (2013.01)]

11 Claims

1. A formulation comprising:

a. 0.1 to 7 wt. % of at least one block copolymer of ethylene oxide and propylene oxide having the structure of ethylene oxide-propylene oxide-ethylene oxide;

b. 0.1 to 5 wt. % of at least one polyacrylic acid salt; and

c. 0.01 to 3 wt. % of at least one propoxylated ethylenediamine compound.